Drug-induced hypertension: An unappreciated cause of secondary hypertension

American Journal of Medicine

Volumn 125, Issue 1, 2012, Pages 14-22

  Grossman, Ehud ^a,b   Messerli, Franz H ^c,d  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^d College of Physicians and Surgeons ^*  (United States)

Author keywords

Hypertension

Indexed keywords

ADRENALIN; ANTIDEPRESSANT AGENT; ANTIRETROVIRUS AGENT; AXITINIB; BEVACIZUMAB; CLOZAPINE; CORTICOSTEROID; DANAZOL; FENTANYL CITRATE; HERBACEOUS AGENT; IMMUNOSUPPRESSIVE AGENT; KETAMINE; KETOCONAZOLE; LAPATINIB; METHYLPHENIDATE; MONOAMINE OXIDASE INHIBITOR; NAPHAZOLINE; NONSTEROID ANTIINFLAMMATORY AGENT; OXYMETAZOLINE; PAZOPANIB; PHENYLEPHRINE; PLACEBO; PSEUDOEPHEDRINE; RECOMBINANT ERYTHROPOIETIN; SIBUTRAMINE; SODIUM; SORAFENIB; SUNITINIB; TETRYZOLINE; UNINDEXED DRUG;

ADVANCED CANCER; ANGIONEUROTIC EDEMA; ANTIANGIOGENIC THERAPY; ANTIHYPERTENSIVE ACTIVITY; ARTERIOLE; BLOOD PRESSURE; BREAST CANCER; COLON CANCER; DIASTOLIC BLOOD PRESSURE; DRUG INDUCED DISEASE; DRUG INDUCED HYPERTENSION; DRUG MECHANISM; ENDOMETRIOSIS; ESSENTIAL HYPERTENSION; GLIOBLASTOMA; GLYCYRRHIZA; HUMAN; HYPERTENSION; HYPERTENSION ENCEPHALOPATHY; HYPOKALEMIA; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY FAILURE; LIVER CELL CARCINOMA; METABOLIC ALKALOSIS; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RECTUM CANCER; REVIEW; SIDE EFFECT; SODIUM RETENTION; STROKE; SYSTOLIC BLOOD PRESSURE; VASCULAR SMOOTH MUSCLE;

ADRENAL CORTEX HORMONES; ALCOHOL DRINKING; ANTI-HIV AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIDEPRESSIVE AGENTS; CAFFEINE; COCAINE; DRUG THERAPY; ERYTHROPOIETIN; GLYCYRRHIZA; GONADAL STEROID HORMONES; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; PHARMACEUTICAL PREPARATIONS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84455178883     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2011.05.024     Document Type: Review

References (74)

1. W.J. Elliott Drug interactions and drugs that affect blood pressure J Clin Hypertens (Greenwich) 8 10 2006 731 737
2. E. Grossman, F.H. Messerli High blood pressure A side effect of drugs, poisons, and food Arch Intern Med 155 5 1995 450 460
3. H. Hurwitz, L. Fehrenbacher, W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 23 2004 2335 2342
4. T. Shih, C. Lindley Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies Clin Ther 28 11 2006 1779 1802
5. H. Izzedine, S. Ederhy, F. Goldwasser Management of hypertension in angiogenesis inhibitor-treated patients Ann Oncol 20 5 2009 807 815
6. M. Kozloff, M.U. Yood, J. Berlin Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study Oncologist 14 9 2009 862 870
7. F. Kabbinavar, H.I. Hurwitz, L. Fehrenbacher Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 21 1 2003 60 65
8. K. Lee, H. Yang, H. Lim, H.M. Lew A prospective study of blood pressure and intraocular pressure changes in hypertensive and nonhypertensive patients after intravitreal bevacizumab injection Retina 29 10 2009 1409 1417
9. A. Sheybani, S. Kymes, S. Schlief, R. Apte Vascular events in patients with age-related macular degeneration treated with intraocular bevacizumab Retina 29 10 2009 1404 1408
10. B. Escudier, T. Eisen, W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2 2007 125 134
11. J.M. Llovet, S. Ricci, V. Mazzaferro Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 4 2008 378 390
12. S. Wu, J.J. Chen, A. Kudelka, J. Lu, X. Zhu Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis Lancet Oncol 9 2 2008 117 123
13. M.L. Maitland, K.E. Kasza, T. Karrison Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment Clin Cancer Res 15 19 2009 6250 6257
14. X. Zhu, K. Stergiopoulos, S. Wu Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis Acta Oncol 48 1 2009 9 17
15. C.F. Levy, K.Z. Oo, F. Fireman Reversible posterior leukoencephalopathy syndrome in a child treated with bevacizumab Pediatr Blood Cancer 52 5 2009 669 671
16. J.D. Hood, C.J. Meininger, M. Ziche, H.J. Granger VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells Am J Physiol 274 3 Pt 2 1998 H1054 H1058
17. F.R. Gonzalez-Pacheco, J.J. Deudero, M.C. Castellanos Mechanisms of endothelial response to oxidative aggression: protective role of autologous VEGF and induction of VEGFR2 by H2O2 Am J Physiol Heart Circ Physiol 291 3 2006 H1395 H1401
18. M.H. Kappers, J.H. van Esch, W. Sluiter, S. Sleijfer, A.H. Danser, A.H. van den Meiracker Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels Hypertension 56 4 2010 675 681
19. P. Bono, H. Elfving, T. Utriainen Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma Ann Oncol 20 2 2009 393 394
20. L.Y. Dirix, H. Maes, C. Sweldens Treatment of arterial hypertension (AHT) associated with angiogenesis inhibitors Ann Oncol 18 6 2007 1121 1122
21. M. Kletzel, N. Jaffe Systemic hypertension: complication of intra-arterial cis-diammine dichloroplatinum (II) infusion Cancer 47 2 1981 245 247
22. A.G. Johnson NSAIDs and increased blood pressure What is the clinical significance? Drug Saf 17 5 1997 277 289
23. H. Krum, G. Swergold, S.P. Curtis Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study J Hypertens 27 4 2009 886 893
24. T. Morgan, A. Anderson The effect of nonsteroidal anti-inflammatory drugs on blood pressure in patients treated with different antihypertensive drugs J Clin Hypertens (Greenwich) 5 1 2003 53 57
25. E.P. Armstrong, D.C. Malone The impact of nonsteroidal anti-inflammatory drugs on blood pressure, with an emphasis on newer agents Clin Ther 25 1 2003 1 18
26. T.J. Aw, S.J. Haas, D. Liew, H. Krum Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure Arch Intern Med 165 5 2005 490 496
27. C.C. Chan, C.M. Reid, T.J. Aw, D. Liew, S.J. Haas, H. Krum Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis J Hypertens 27 12 2009 2332 2341
28. J. Wang, C.D. Mullins, M. Mamdani, D.A. Rublee, F.T. Shaya New diagnosis of hypertension among celecoxib and nonselective NSAID users: a population-based cohort study Ann Pharmacother 41 6 2007 937 943
29. J.R. Sowers, W.B. White, B. Pitt The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus Arch Intern Med 165 2 2005 161 168
30. S.D. Solomon, M.A. Pfeffer, J.J. McMurray Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas Circulation 114 10 2006 1028 1035
31. M.A. Weber Treatment of patients with hypertension and arthritis pain: new concepts Am J Med 122 5 Suppl 2009 S16 S22
32. F.H. Messerli Aspirin: a novel antihypertensive drug? Or two birds with one stone? J Am Coll Cardiol 46 6 2005 984 985
33. W.B. White Cardiovascular effects of the cyclooxygenase inhibitors Hypertension 49 3 2007 408 418
34. J.P. Forman, E.B. Rimm, G.C. Curhan Frequency of analgesic use and risk of hypertension among men Arch Intern Med 167 4 2007 394 399
35. B. Montgomery Does paracetamol cause hypertension? BMJ 336 7654 2008 1190 1191
36. G.C. Curhan, W.C. Willett, B. Rosner, M.J. Stampfer Frequency of analgesic use and risk of hypertension in younger women Arch Intern Med 162 19 2002 2204 2208
37. I. Pavlicevic, M. Kuzmanic, M. Rumboldt, Z. Rumboldt Interaction between antihypertensives and NSAIDs in primary care: a controlled trial Can J Clin Pharmacol 15 3 2008 e372 e382
38. K.L. Radack, C.C. Deck, S.S. Bloomfield Ibuprofen interferes with the efficacy of antihypertensive drugs A randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen Ann Intern Med 107 5 1987 628 635
39. I. Sudano, A.J. Flammer, D. Periat Acetaminophen increases blood pressure in patients with coronary artery disease Circulation 122 18 2010 1789 1796
40. B. Hinz, O. Cheremina, K. Brune Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man FASEB J 22 2 2008 383 390
41. A. Bertolini, A. Ferrari, A. Ottani, S. Guerzoni, R. Tacchi, S. Leone Paracetamol: new vistas of an old drug CNS Drug Rev 12 3-4 2006 250 275
42. M.E. Thase Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients J Clin Psychiatry 59 10 1998 502 508
43. L. Chasan-Taber, W.C. Willett, J.E. Manson Prospective study of oral contraceptives and hypertension among women in the United States Circulation 94 3 1996 483 489
44. S.F. Hussain Progestogen-only pills and high blood pressure: is there an association? A literature review Contraception 69 2 2004 89 97
45. P. Affinito, S. Palomba, M. Bonifacio Effects of hormonal replacement therapy in postmenopausal hypertensive patients Maturitas 40 1 2001 75 83
46. D.L. Cohen, R.R. Townsend Does consumption of high-caffeine energy drinks affect blood pressure? J Clin Hypertens (Greenwich) 8 10 2006 744 745
47. M.R. Savoca, M.L. MacKey, C.D. Evans, M. Wilson, D.A. Ludwig, G.A. Harshfield Association of ambulatory blood pressure and dietary caffeine in adolescents Am J Hypertens 18 1 2005 116 120
48. M. Noordzij, C.S. Uiterwaal, L.R. Arends, F.J. Kok, D.E. Grobbee, J.M. Geleijnse Blood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trials J Hypertens 23 5 2005 921 928
49. S. Bangalore, S. Parkar, F.H. Messerli "One" cup of coffee and nuclear SPECT to go J Am Coll Cardiol 49 4 2007 528 author reply 528-529
50. A.A. Izzo, G. Di Carlo, F. Borrelli, E. Ernst Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction Int J Cardiol 98 1 2005 1 14
51. C.A. Haller, N.L. Benowitz Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids N Engl J Med 343 25 2000 1833 1838
52. D.V. Awang, A. Fugh-Berman Herbal interactions with cardiovascular drugs J Cardiovasc Nurs 16 4 2002 64 70
53. B.A. Johnson, L.T. Wells, J.D. Roache, C. Wallace, N. Ait-Daoud, Y. Wang Isradipine decreases the hemodynamic response of cocaine and methamphetamine results from two human laboratory studies: results from two human laboratory studies Am J Hypertens 18 6 2005 813 822
54. C. Ponticelli Cyclosporine in idiopathic nephrotic syndrome Immunopharmacol Immunotoxicol 15 4 1993 479 489
55. R. Snanoudj, F. Kriaa, N. Arzouk Single-center experience with cyclosporine therapy for kidney transplantation: analysis of a twenty-year period in 1200 patients Transplant Proc 36 2 Suppl 2004 83S 88S
56. T.P. Loughran Jr, H.J. Deeg, S. Dahlberg, M.S. Kennedy, R. Storb, E.D. Thomas Incidence of hypertension after marrow transplantation among 112 patients randomized to either cyclosporine or methotrexate as graft-versus-host disease prophylaxis Br J Haematol 59 3 1985 547 553
57. R. Cifkova, H. Hallen Cyclosporin-induced hypertension J Hypertens 19 12 2001 2283 2285
58. J.L. Rodicio Calcium antagonists and renal protection from cyclosporine nephrotoxicity: long-term trial in renal transplantation patients J Cardiovasc Pharmacol 35 3 2000 S7 S11
59. T.M. Manzia, N. De Liguori Carino, G. Orlando Use of mycophenolate mofetil in liver transplantation: a literature review Transplant Proc 37 6 2005 2616 2617
60. J.M. Morales, A. Andres, M. Rengel, J.L. Rodicio Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation Nephrol Dial Transplant 16 Suppl 1 2001 121 124
61. B.L. Novak, R.W. Force, B.T. Mumford, R.M. Solbrig Erythropoietin-induced hypertensive urgency in a patient with chronic renal insufficiency: case report and review of the literature Pharmacotherapy 23 2 2003 265 269
62. A.L. Klatsky, G.D. Friedman, A.B. Siegelaub, M.J. Gerard Alcohol consumption and blood pressure Kaiser-Permanente Multiphasic Health Examination data N Engl J Med 296 21 1977 1194 1200
63. S.W. MacMahon, R.B. Blacket, G.J. Macdonald, W. Hall Obesity, alcohol consumption and blood pressure in Australian men and women The National Heart Foundation of Australia Risk Factor Prevalence Study J Hypertens 2 1 1984 85 91
64. K. Yoshita, K. Miura, Y. Morikawa Relationship of alcohol consumption to 7-year blood pressure change in Japanese men J Hypertens 23 8 2005 1485 1490
65. J.M. Grandominico, C.J. Fichtenbaum Short-term effect of HAART on blood pressure in HIV-infected individuals HIV Clin Trials 9 1 2008 52 60
66. M. Baekken, I. Os, L. Sandvik, O. Oektedalen Hypertension in an urban HIV-positive population compared with the general population: influence of combination antiretroviral therapy J Hypertens 26 11 2008 2126 2133
67. T.R. Glass, C. Ungsedhapand, M. Wolbers Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study HIV Med 7 6 2006 404 410
68. H.M. Crane, S.E. Van Rompaey, M.M. Kitahata Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy AIDS 20 7 2006 1019 1026
69. A.M. Cattelan, M. Trevenzoli, A. Naso, F. Meneghetti, P. Cadrobbi Severe hypertension and renal atrophy associated with indinavir Clin Infect Dis 30 3 2000 619 621
70. V. Khurana, M. de la Fuente, T.P. Bradley Hypertensive crisis secondary to phenylpropanolamine interacting with triple-drug therapy for HIV prophylaxis Am J Med 106 1 1999 118 119
71. C.J. Fichtenbaum, J.G. Gerber Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection Clin Pharmacokinet 41 14 2002 1195 1211
72. T. Tapaninen, P.J. Neuvonen, M. Niemi Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren Eur J Clin Pharmacol 66 5 2010 497 502
73. N. Holtbecker, M.F. Fromm, H.K. Kroemer, E.E. Ohnhaus, H. Heidemann The nifedipine-rifampin interaction Evidence for induction of gut wall metabolism Drug Metab Dispos 24 10 1996 1121 1123
74. A. Marney, S. Kunchakarra, L. Byrne, N.J. Brown Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans Hypertension 56 4 2010 728 733